HSD17B13 and diabetes mellitus: Subgroup analyses stratified by baseline fibrosis stage, diabetes status, and genetic polymorphisms (particularly PNPLA3, TM6SF2, and HSD17B13 variants) could identify patients most likely to benefit from SGLT2 inhibitor therapy.